FDA Awards Nearly $3M for TB Research

Published: 2010-10-05
Author: U.S. Food and Drug Administration
Peer-Reviewed: N/A
Related Papers: Latest Items - Full List

On This Page: Summary - Main Article

Synopsis: Grant to support research projects that will help with the diagnosis treatment and prevention of tuberculosis (TB). The U.S. Food and Drug Administration today announced the award of $2.9 million to support six research projects that will help with the diagnosis, treatment, and prevention of tuberculosis (TB).

Main Digest

The U.S. Food and Drug Administration today announced the award of $2.9 million to support six research projects that will help with the diagnosis, treatment, and prevention of tuberculosis (TB).

TB remains a major public health challenge with an increasing prevalence worldwide. Two recent articles published by FDA's Office of Critical Path Programs note that advances are urgently needed in TB drug development to shorten therapy and to treat drug-resistant disease.

"FDA recognized an urgent need for the engagement and leadership of public health institutions to promote this critical, but neglected, area of medical therapeutics," said FDA Commissioner Margaret A. Hamburg, M.D.

Funded with congressional support in FY2010, the following six grantees were chosen from among 30 applications:

Michael Brennan, Ph.D., Aeras Global TB Vaccine Foundation - Discovery of biological and immunological biomarkers for TB vaccines

Ann Ginsberg, M.D., Ph.D., Global Alliance for TB Drug Development - Frozen trials, developing a repository of clinical trial specimens

Khisimuzi Mdluli, Ph.D., Global Alliance of TB Drug Development - Qualifying new preclinical models for the development of tuberculosis drug combinations

Fred Quinn, Ph.D., the University of Georgia Research Foundation Inc. - Development of a diagnostic for latent TB

John T. Belisle, Ph.D., Colorado State University - Small molecule biomarkers for tuberculosis treatment, relapse, and cure

Marc D. Porter, Ph.D., the University of Utah - Development and validation of point-of-care tests for tuberculosis (ultra-sensitive SERS detection technology for low concentration antigens).

Launched in 2004, the Critical Path Initiative is the FDA's strategy for driving innovation in the way medical products are developed, evaluated, and manufactured.

For more information: FDA Critical Path Initiative - www.fda.gov/CriticalPath

Share This Information To:
𝕏.com Facebook Reddit

Discover Related Topics:

Information, Citing and Disclaimer

Disabled World is an independent disability community founded in 2004 to provide disability news and information to people with disabilities, seniors, their family and/or carers. See our homepage for informative reviews, exclusive stories and how-tos. You can connect with us on social media such as X.com and our Facebook page.

Permalink: <a href="https://www.disabled-world.com/disability/finance/tb-research-grant.php">FDA Awards Nearly $3M for TB Research</a>

Cite This Page (APA): U.S. Food and Drug Administration. (2010, October 5). FDA Awards Nearly $3M for TB Research. Disabled World. Retrieved September 23, 2023 from www.disabled-world.com/disability/finance/tb-research-grant.php

Disabled World provides general information only. The materials presented are never meant to substitute for qualified professional medical care, nor should they be construed as such. Funding is derived from advertisements or referral programs. Any 3rd party offering or advertising does not constitute an endorsement.